Results 171 to 180 of about 433,923 (290)

Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma. [PDF]

Biology (Basel)
Ahmady-Nield F, Luwor RB, Kannourakis G.
europepmc   +1 more source

Prognostic Determinants of Overall Survival After Resection for Pancreatic Ductal Adenocarcinoma: A Consensus‐Based Conceptual Framework

Journal of Surgical Oncology, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis despite surgical resection, yet the prognostic literature remains fragmented across hundreds of single‐institution studies that vary in design, covariates, and analytical approaches.
Muhammad Maisam Ali, Kaleem S. Ahmed, Clayton T. Marcinak, Syed Ali Tayyeb Hasan, Anne D. Letocha, Noorain Ahmad, Haider bin Khalid, Kainat Fatima, Syed Nabeel Zafar   +8 more
wiley   +1 more source

Outcomes Following Total Pancreatectomy With and Without Vascular Resection: A NSQIP Analysis Comparing Trends in Patient Selection and Outcomes Over 5 Years

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction Advances in neoadjuvant therapy and surgical techniques have led to more total pancreatectomies (TP) with vascular resection for pancreatic cancer. This study assesses contemporary outcomes of TP with venous (VR) and arterial (AR) resections compared to non‐vascular resection (NVR).
Zofia Czarnecka, Kevin Verhoeff, A. M. James Shapiro, Chaya Shwaartz   +3 more
wiley   +1 more source

Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes, Local Control, and Survival?

Journal of Surgical Oncology, EarlyView.
ABSTRACT Objectives Neoadjuvant chemoradiation for PDAC with vascular invasion remains understudied. The aim of this study is to compare neoadjuvant chemotherapy with chemoradiation (NAC + CRT) versus neoadjuvant chemotherapy (NAC) for PDAC with vascular involvement.
Dhruv J. Patel, Lauren M. Janczewski, Joseph H. Cotler, George Molina, Brett L. Ecker, David Bentrem, Shishir K. Maithel, Mohamed E. Abazeed, John P. Hayes, Bryan Palis, Amanda B. Francescatti, Ronald J. Weigel, Judy Boughey, Lesly Dossett, Akhil Chawla   +14 more
wiley   +1 more source

Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma. [PDF]

Cells
De Luca M, Balestra F, Panzetta G, Giannelli G, Scavo MP.   +4 more
europepmc   +1 more source

Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real‐World Population

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction The PRODIGE 24/CCTG PA.6‐ trial has shown an overall survival (OS) up to 55 months in patients treated with (modified) 5‐fluorouracil, leucovorin, irinotecan and oxaliplatin ((m)FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). The applicability of these results to a real‐world patient population
N. C. Biesma, G. A. Cirkel, N. Haj Mohammad, M. Los, R. C. Verdonk, I. Q. Molenaar, L. A. Daamen, H. C. van Santvoort   +7 more
wiley   +1 more source

Intrapancreatic Fat and Risk of Pancreatic Ductal Adenocarcinoma-Pathophysiology, Clinical Implications, and Future Directions. [PDF]

Int J Mol Sci
Meyhöfer S, Lünswilken P, Grammatopoulos D, Randeva H, Marquardt JU, Lehnert H.   +5 more
europepmc   +1 more source

Heterogeneity Analyzed by CT‐Based Habitat Analysis for Clinical Management of Cancers: A Narrative Review

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Tumors are highly heterogeneous, and whole‐lesion radiomics analysis is a popular method for extracting texture features that reflect this heterogeneity, which can be used to build models for cancer diagnosis, staging, therapy response evaluation, and prognosis prediction.
Yang Zhang, Zhi‐Yan Jin, Min‐Ying Lydia Su   +2 more
wiley   +1 more source

Desmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma. [PDF]

Cancer Lett
Ghanwatkar Y, Ramanathan R, Mahato RI.
europepmc   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source